For research use only. Not for therapeutic Use.
Asperuloside is an iridoid isolated from Hedyotis diffusa, with anti-inflammatory activity. Asperuloside inhibits inducible nitric oxide synthase (iNOS), suppresses NF-κB and MAPK signaling pathways[1].
Asperuloside (0-160 μg/mL, 1 h) inhibits productions of NO, PGE2, TNF-α and IL-6 in LPS-Induced RAW 264.7 cells[1].
Asperuloside (0-5 mM, 24 h) inhibits cell viability and induces ER stress dependent apoptosis in leukemia cell lines (U937, HL-60, AML)[1].
Asperuloside (p.o., 3 mg/day, 0.3% in diet, daily, 12 weeks) reduces food intake, body weight, and adipose masses in rats consuming a high fat diet (HFD)[2].
Asperuloside (30 and 60 mg/kg, i.p., 30 days) inhibits tumor growth of U937 xenografts mice model[3].
Asperuloside (20-80 mg/kg, i.p.) relieves LPS-induced acute lung injury via inhibiting MAPK and NF-κB signaling in BALB/c mice[4].
| Catalog Number | M064301 |
| CAS Number | 14259-45-1 |
| Synonyms | [(4S,7S,8S,11S)-2-oxo-8-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,9-dioxatricyclo[5.3.1.04,11]undeca-1(10),5-dien-6-yl]methyl acetate |
| Molecular Formula | C18H22O11 |
| Purity | ≥95% |
| InChI | InChI=1S/C18H22O11/c1-6(20)25-4-7-2-9-12-8(16(24)27-9)5-26-17(11(7)12)29-18-15(23)14(22)13(21)10(3-19)28-18/h2,5,9-15,17-19,21-23H,3-4H2,1H3/t9-,10+,11+,12-,13+,14-,15+,17-,18-/m0/s1 |
| InChIKey | IBIPGYWNOBGEMH-DILZHRMZSA-N |
| SMILES | CC(=O)OCC1=CC2C3C1C(OC=C3C(=O)O2)OC4C(C(C(C(O4)CO)O)O)O |
| Reference | [1]. He J, et al. Asperuloside and Asperulosidic Acid Exert an Anti-Inflammatory Effect via Suppression of the NF-κB and MAPK Signaling Pathways in LPS-Induced RAW 264.7 Macrophages. Int J Mol Sci. 2018 Jul 12;19(7). [2]. Ishaq M, et al. Asperuloside Enhances Taste Perception and Prevents Weight Gain in High-Fat Fed Mice. Front Endocrinol (Lausanne). 2021 Apr 13;12:615446. [3]. Rong C, et al. Asperuloside exhibits a novel anti-leukemic activity by triggering ER stress-regulated apoptosis via targeting GRP78. Biomed Pharmacother. 2020 May;125:109819. [4]. Qiu J, et al. Pretreatment with the compound asperuloside decreases acute lung injury via inhibiting MAPK and NF-κB signaling in a murine model. Int Immunopharmacol. 2016 Feb;31:109-15. |
